Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design
about
An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patientsRilpivirine: a new non-nucleoside reverse transcriptase inhibitorCurrent perspectives on HIV-1 antiretroviral drug resistanceStructural and Binding Analysis of Pyrimidinol Carboxylic Acid and N-Hydroxy Quinazolinedione HIV-1 RNase H InhibitorsStructure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse TranscriptaseA mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptaseIdentification of a novel sulfonamide non-nucleoside reverse transcriptase inhibitor by a phenotypic HIV-1 full replication assayNovel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.HIV-1 antiretroviral drug therapy.New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.Role of Ligand Reorganization and Conformational Restraints on the Binding Free Energies of DAPY Non-Nucleoside Inhibitors to HIV Reverse Transcriptase.Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.Biochemical mechanism of HIV-1 resistance to rilpivirine.Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP.Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Conformational Plasticity of the NNRTI-Binding Pocket in HIV-1 Reverse Transcriptase: A Fluorine Nuclear Magnetic Resonance Study.Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsThe connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant VirusIn search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs).Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants.Design, synthesis, and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs.Discovery of piperidine-linked pyridine analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1.NMR structure of the HIV-1 reverse transcriptase thumb subdomain.Molecular insight on the binding of NNRTI to K103N mutated HIV-1 RT: molecular dynamics simulations and dynamic pharmacophore analysis.Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections.Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.Design, Synthesis, and Anti-HIV Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the NNRTI Binding Pocket.Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics.Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.
P2860
Q26827791-7E77DC2F-0F0A-45CE-91FE-D923CDA9ADBCQ26830730-51F0A3EA-45FF-469B-A981-25D7DC0C4304Q26852626-7060FC63-AA73-4588-9D12-60F0F3E2AEFFQ27667421-AF472EC1-DEAE-4F63-A464-EAF1CC1473D6Q27680709-7FB468B7-9BF7-453E-BAAB-52C20D5B502DQ27683249-9B9EF47F-7FBC-4FA1-AF9F-9C76A4F1C237Q28534728-A3EB78B7-743A-4EC4-A474-817C988BC328Q30363318-55920B8A-2773-4D3F-A431-985BC03D057CQ33630579-3629A3A2-07CA-4B47-90A8-D4826E14F7B3Q33649797-CDF4B393-B0EE-4182-87FB-8630C7902C68Q34035045-EA5AA8B1-BC3F-4555-A7A5-CA3AB34C3711Q35228851-5ABE2842-61FC-41CD-967B-7E3564BCFEB6Q35853012-AE43C959-85EE-4117-BE8E-46DE9E791E08Q35939695-6559B598-7021-4F28-AE6B-48CBA34C0CAEQ35944914-5959C42F-BBC3-4D64-8619-90279D7E995AQ36029898-3883C417-B371-443D-8E67-5C6DBEB676D3Q36146704-64A9D7F4-601F-4DAB-B2A9-9734C8420C26Q36368294-467DD567-827E-469C-9B4C-BA69371BDF64Q36939750-34D0E507-9428-47CB-A33C-823FB814AAA7Q36969977-F715AB10-32F8-4A78-A110-ED12A3C6903DQ37114525-59D6B236-13A3-436A-9587-9A7C56EB3B6AQ37263541-C0E35C6F-E757-450A-B749-518CBB3DAE03Q37547275-C82611E8-A806-461E-8B8C-30D45DFA19EBQ37550710-6A311D5D-CCD6-48AE-BC66-7C16F676B453Q38012389-5B40E673-8142-4325-BDB2-3E07431E5358Q38164839-FA7E9363-70E7-4DBD-A269-196D5AC9DF77Q38272654-4161E265-343F-4AF2-A134-B173F9E0A026Q38620336-FB8A1F3C-C05D-4773-8B09-69767CA16644Q39154248-4C5C0A2D-7984-48B5-B91E-6C4270D69588Q39155306-A2E17A8B-2AC9-4B38-A90B-FD3D28A154DEQ39169967-2325B0BC-13DC-4891-B403-93E5600B2E86Q39178488-5A2A9D92-4038-4F1D-B19B-C2B25C9C1C71Q39306655-F1E2C1BF-F797-466A-881B-A860D27C67E7Q39635884-580FF1E0-7EEC-4BC3-9789-952258D00D9EQ41040182-94360AAC-9A1C-4A20-9F6B-604D4D5C0E9CQ41534943-336A8928-3645-4A6E-BDD4-E82A1108B20FQ42170864-364B7DDA-6286-4264-8227-91A83918B08DQ42182509-1E7C4553-F744-45FF-9455-19DD97D28A1DQ42281612-1C53E945-2D15-43DA-A6E8-59998DEE8ACEQ42718706-77FC05E2-18BC-482C-8E65-3D1CD34AA31E
P2860
Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Crystal structures of HIV-1 re ...... : implications for drug design
@ast
Crystal structures of HIV-1 re ...... : implications for drug design
@en
Crystal structures of HIV-1 re ...... : implications for drug design
@nl
type
label
Crystal structures of HIV-1 re ...... : implications for drug design
@ast
Crystal structures of HIV-1 re ...... : implications for drug design
@en
Crystal structures of HIV-1 re ...... : implications for drug design
@nl
prefLabel
Crystal structures of HIV-1 re ...... : implications for drug design
@ast
Crystal structures of HIV-1 re ...... : implications for drug design
@en
Crystal structures of HIV-1 re ...... : implications for drug design
@nl
P2093
P356
P1476
Crystal structures of HIV-1 re ...... : implications for drug design
@en
P2093
Eric B Lansdon
Katherine M Brendza
Magdeleine Hung
Nilima Kutty
Susmith Mukund
Xiaohong Liu
P304
P356
10.1021/JM1002233
P407
P577
2010-05-01T00:00:00Z